US FDA, EMEA look to harmonise postmarketing surveillance

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2007年 / 1152卷 / 1期

关键词：

Public Health; European Commission; Risk Management; Regulatory Agency; Information Sharing;

D O I：

10.2165/00128415-200711520-00003

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] US FDA posts report on postmarketing surveillance
Reactions Weekly, 2019, 1766 (1) : 3 - 3
[2] US FDA enhancing postmarketing drug safety surveillance
Reactions Weekly, 2019, 1780 (1) : 3 - 3
[3] US FDA addresses postmarketing drug surveillance concerns
Reactions Weekly, 2004, 1030 (1) : 3 - 3
[4] US FDA Enhancing Postmarketing Drug Safety Surveillance
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
[5] FDA will increase postmarketing surveillance of drugs
Tanne, JH
BRITISH MEDICAL JOURNAL, 2004, 329 (7476): : 1203 - 1203
[6] The US FDA has requested proposals for an active postmarketing surveillance hospital pilot programme
Reactions Weekly, 1999, 753 (1) : 2 - 2
[7] How to get the data? Scrutiny of postmarketing surveillance at the FDA
不详
HEALTH AFFAIRS, 2005, 24 (04) : 927 - 927
[8] FDA finalises guidance on its postmarketing safety surveillance
Reactions Weekly, 2024, 1995 (1) : 2 - 2
[9] SHOULD THE PHILOSOPHY OF POSTMARKETING SURVEILLANCE IN THE US BE REDEFINED
SOTO, J
SACRISTAN, JA
PHARMACOECONOMICS, 1995, 8 (02) : 175 - 176
[10] POSTMARKETING SURVEILLANCE AND STATUS OF PHARMACY DISCUSSED BY FDA COMMISSIONER GOYAN
GOYAN, JE
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1980, 37 (06): : 886 - 888

← 1 2 3 4 5 →